411 related articles for article (PubMed ID: 33228726)
21. Effects of sang-qi granules on blood pressure and endothelial dysfunction in stage I or II hypertension: study protocol for a randomized double-blind double-simulation controlled trial.
Shi H; Yang D; Qiao J; Sun R; Li R; Zhu C; Jing R; Liu L; Huang L; Li L
Trials; 2020 Jan; 21(1):12. PubMed ID: 31907056
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of Yiqi Peiyuan granules for improving the short-term prognosis of patients with acute kidney injury: A multicenter, double-blind, placebo-controlled, randomized trial.
Wu JJ; Zhang TY; Qi YH; Zhu MY; Fang Y; Qi CJ; Cao LO; Lu JF; Lu BH; Tang LM; Shen JX; Mou S
J Integr Med; 2024 May; 22(3):279-285. PubMed ID: 38688809
[TBL] [Abstract][Full Text] [Related]
23. 'Huang Qi Elixir' for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial.
Tu X; Liu F; Jordan JB; Ye XF; Fu P; Wang F; Zhong S
Trials; 2013 Jul; 14():223. PubMed ID: 23866835
[TBL] [Abstract][Full Text] [Related]
24. FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Kim JY; Son JW; Park S; Yoo TH; Kim YJ; Ryu DR; Chin HJ
Trials; 2017 Dec; 18(1):632. PubMed ID: 29284530
[TBL] [Abstract][Full Text] [Related]
25. Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial.
Mao W; Yang N; Zhang L; Li C; Wu Y; Ouyang W; Xu P; Zou C; Pei C; Shi W; Zhan J; Yang H; Chen H; Wang X; Tian Y; Yuan F; Sun W; Xiong G; Chen M; Guan J; Tang S; Zhang C; Liu Y; Deng Y; Lin Q; Lu F; Hong W; Yang A; Fang J; Rao J; Wang L; Bao K; Lin F; Xu Y; Lu Z; Su G; Zhang L; Johnson DW; Zhao D; Hou H; Fu L; Guo X; Yang L; Qin X; Wen Z; Liu X
Front Pharmacol; 2020; 11():627185. PubMed ID: 33708125
[TBL] [Abstract][Full Text] [Related]
26. Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease.
Mao W; Zhang L; Zou C; Li C; Wu Y; Su G; Guo X; Wu Y; Lu F; Lin Q; Wang L; Bao K; Xu P; Zhao D; Peng Y; Liang H; Lu Z; Gao Y; Jie X; Zhang L; Wen Z; Liu X
BMC Complement Altern Med; 2015 Sep; 15():316. PubMed ID: 26351087
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study.
Zheng Y; Cai GY; He LQ; Lin HL; Cheng XH; Wang NS; Jian GH; Liu XS; Liu YN; Ni ZH; Fang JA; Ding HL; Guo W; He YN; Wang LH; Wang YP; Yang HT; Ye ZM; Yu RH; Zhao LJ; Zhou WH; Li WG; Mao HJ; Zhan YL; Hu Z; Yao C; Wei RB; Chen XM
Chin Med J (Engl); 2017 Oct; 130(20):2402-2409. PubMed ID: 29052559
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial.
Lai X; Dong Z; Wu S; Zhou X; Zhang G; Xiong S; Wu W; Cao R; Wang X; Hua Q; Du J; Fan J; Mao J; Jiang W; Yuan H; Chen Y; Xu Y; Li Z; Zhang J; Dong G; Zhen H; Ding R; Wu Z; Gao Y
Circ Cardiovasc Qual Outcomes; 2022 Mar; 15(3):e007923. PubMed ID: 35105177
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
Wu QJ; Lv WL; Li JM; Zhang TT; Zhou WH; Zhang Q; Wang JC; Wang QN; Zhang RX; Zhao X; Chen ST; Liu S; Li GH; Cao ZM; Xu L; Chen J
Trials; 2020 Jun; 21(1):482. PubMed ID: 32503608
[TBL] [Abstract][Full Text] [Related]
30. The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.
Yoo TH; Hong SJ; Kim S; Shin S; Kim DK; Lee JP; Han SY; Lee S; Won JC; Kang YS; Park J; Han BG; Na KR; Hur KY; Kim YJ; Park S
Hypertens Res; 2022 Dec; 45(12):2008-2017. PubMed ID: 36123398
[TBL] [Abstract][Full Text] [Related]
31. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial.
Leehey DJ; Carlson K; Reda DJ; Craig I; Clise C; Conner TA; Agarwal R; Kaufman JS; Anderson RJ; Lammie D; Huminik J; Polzin L; McBurney C; Huang GD; Emanuele NV
BMJ Open; 2021 Aug; 11(8):e053019. PubMed ID: 34400461
[TBL] [Abstract][Full Text] [Related]
32. Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomised placebo-controlled trials.
Zhang L; Yang L; Shergis J; Zhang L; Zhang AL; Guo X; Qin X; Johnson D; Liu X; Lu C; Xue CC; Mao W
BMJ Open; 2019 May; 9(4):e025653. PubMed ID: 31048437
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Eissing T; Goulooze SC; van den Berg P; van Noort M; Ruppert M; Snelder N; Garmann D; Lippert J; Heinig R; Brinker M; Heerspink HJL
Diabetes Obes Metab; 2024 Mar; 26(3):924-936. PubMed ID: 38037539
[TBL] [Abstract][Full Text] [Related]
34. Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial.
Lyu J; Xie YM; Gao Z; Shen JW; Deng YY; Xiang ST; Gao WX; Zeng WT; Zhang CH; Yi DH; Wang LX; Wang ZF
Trials; 2019 Jul; 20(1):446. PubMed ID: 31324199
[TBL] [Abstract][Full Text] [Related]
35. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
[TBL] [Abstract][Full Text] [Related]
36. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.
Shen Z; Zheng K; Zou J; Gu P; Xing J; Zhang L; Zhu L; Shen H
Trials; 2021 Jan; 22(1):55. PubMed ID: 33441157
[TBL] [Abstract][Full Text] [Related]
37. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
38. Correlation Between Serum 25-Hydroxyvitamin D Levels in Albuminuria Progression of Diabetic Kidney Disease and Underlying Mechanisms By Bioinformatics Analysis.
Huang B; Wen W; Ye S
Front Endocrinol (Lausanne); 2022; 13():880930. PubMed ID: 35634488
[TBL] [Abstract][Full Text] [Related]
39. Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial.
Jin D; Huang WJ; Meng X; Yang F; Zheng YJ; Bao Q; Zhang MZ; Yang YN; Ni Q; Lian FM; Tong XL
Trials; 2017 Dec; 18(1):631. PubMed ID: 29284520
[TBL] [Abstract][Full Text] [Related]
40. Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Chen W; Lin J; Yang T; Xin Zhang Z; Tao L; Xiao Z; Chen H; Qi X; Sun L; Cao Y; Lin L
Integr Cancer Ther; 2023; 22():15347354221151147. PubMed ID: 36710490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
